Back to Results

Phathom Pharmaceuticals Inc (PHAT)

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases in the United States. Its lead program includes VOQUEZNA, which has completed Phase III clinical trials for erosive gastroesophageal reflux disease (GERD) and related heartburn in adults. The company is also advancing VOQUEZNA Triple Pak and VOQUEZNA Dual Pak, both of which have completed Phase III clinical trials for Helicobacter pylori treatment. Additional development efforts include VOQUEZNA and vonoprazan for heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. Founded in 2018, Phathom Pharmaceuticals is headquartered in Florham Park, New Jersey.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-PHAT
$7.25
-6.6% Downside
Fair
$20.45
163.6% Upside
Bargain
Fair
0.0%
November 5, 2026
2.5x
616.4 M
961.3 M
48.3%
80.7%
-5.2
37.3%
Valuation • Fair Value

Phathom Pharmaceuticals Inc (NASDAQ-PHAT) Fair Value by Valuation Model

Review the available estimates for Phathom Pharmaceuticals Inc (NASDAQ-PHAT), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$7.25

Estimated downside of 6.6% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$13.06

Discounted cash flow valuation reference.

Comps Fair Value

$6.28

Comparable-company valuation reference.

Analyst Price Target

$20.45

Analysts imply upside of 163.6%.

How to read these valuation models

Use the 5 available valuation references for Phathom Pharmaceuticals Inc (NASDAQ-PHAT) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Phathom Pharmaceuticals Inc (NASDAQ-PHAT)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

239.7 M

Current operating scale indicator.

Revenue Forecast

316.2 M

Forward revenue estimate.

EBITDA

-40.134 M

Current operating profitability reference.

EBITDA Forecast

12.329 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Phathom Pharmaceuticals Inc (NASDAQ-PHAT) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Phathom Pharmaceuticals Inc (NASDAQ-PHAT)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-2.27

No elevated caution signal from this screen.

Altman Z-Score

-5.2

Lower score that deserves closer risk review.

FCF / Net Income

37.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Phathom Pharmaceuticals Inc (NASDAQ-PHAT). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Phathom Pharmaceuticals Inc (NASDAQ-PHAT)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 5, 2026

Days to Earnings

44

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Phathom Pharmaceuticals Inc (NASDAQ-PHAT), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Phathom Pharmaceuticals Inc (NASDAQ-PHAT) Stock Forecast & Technical Outlook

Review Phathom Pharmaceuticals Inc (NASDAQ-PHAT) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Phathom Pharmaceuticals Inc (NASDAQ-PHAT) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Buy

The 1-hour technical read for Phathom Pharmaceuticals Inc (NASDAQ-PHAT) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Phathom Pharmaceuticals Inc (NASDAQ-PHAT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Phathom Pharmaceuticals Inc (NASDAQ-PHAT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Phathom Pharmaceuticals Inc (NASDAQ-PHAT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Phathom Pharmaceuticals Inc (NASDAQ-PHAT)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Phathom Pharmaceuticals Inc (NASDAQ-PHAT) has a Strong Buy consensus, with 8 buy, 2 hold and 0 sell recommendations in the current data set.

Buy 8
Hold 2
Sell 0
FAQ • Fast Investor Answers

Phathom Pharmaceuticals Inc (NASDAQ-PHAT) Stock FAQ

Data-supported answers about Phathom Pharmaceuticals Inc (NASDAQ-PHAT), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$7.25
Estimated downside 6.6%
Valuation Rating
Overvalued
Estimated downside of 6.6%
Analyst Target
$20.45
Implied upside 163.6%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Phathom Pharmaceuticals Inc (NASDAQ-PHAT) is $7.25. This implies an estimated downside of 6.6% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 6.6% versus the current market price.

The available analyst price target for Phathom Pharmaceuticals Inc (NASDAQ-PHAT) is $20.45. The analyst target implies estimated upside of 163.6%.

The current financial health read for Phathom Pharmaceuticals Inc (NASDAQ-PHAT) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Phathom Pharmaceuticals Inc (NASDAQ-PHAT) is November 5, 2026.

The latest available data indicates no current dividend yield for Phathom Pharmaceuticals Inc (NASDAQ-PHAT).

The current market capitalization listed for Phathom Pharmaceuticals Inc is 616.4 M.

The current enterprise value listed for Phathom Pharmaceuticals Inc is 961.3 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Phathom Pharmaceuticals Inc is NASDAQ-PHAT, and the stock is listed on NASDAQ.

Phathom Pharmaceuticals Inc (NASDAQ-PHAT) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Phathom Pharmaceuticals Inc is 48.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Phathom Pharmaceuticals Inc is 80.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B